Given the success of (multi-)exon skipping for the future treatment of USH2A-associated retinal dysfunction and the current lack of treatment options for ADGRV1-associated RP, this study aimed to explore whether a similar exon removal strategy—through CRISPR-Cas9-mediated exon excision—could also serve as a therapeutic strategy for this disorder. Here, ADGRV1 is linked to retinitis pigmentosa 1.